Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea

BACKGROUND AND OBJECTIVES: To compare cardiovascular disease (CVD) risk associated with 5 different dipeptidyl peptidase-4 inhibitors (DPP-4is) in people with type 2 diabetes. METHODS: We identified 534,327 people who were newly prescribed sitagliptin (n=167,157), vildagliptin (n=67,412), saxaglipti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Kyoung Hwa, Kim, Bongseong, Shin, Hae Sol, Lee, Jinhee, Choi, Hansol, Kim, Hyeon Chang, Kim, Dae Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940644/
https://www.ncbi.nlm.nih.gov/pubmed/29671284
http://dx.doi.org/10.4070/kcj.2017.0324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940644/
https://www.ncbi.nlm.nih.gov/pubmed/29671284
http://dx.doi.org/10.4070/kcj.2017.0324

Ejemplares similares